Phaseline

Targets › MRSA

MRSA: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Jan 2029.

Open in Phaseline: the race on MRSA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Todd C. Lee MD MPH FIDSADaptomycin for Injection
Lipopeptide antibiotic that disrupts bacterial cell membrane; bactericidal against Gram-po
MRSAPhase 4Staphylococcus Aureus SepticemiaJan 2029

Conditions

Staphylococcus Aureus Septicemia (1)

Modalities

small molecule (1)

Companies

Todd C. Lee MD MPH FIDSA (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.